News

Filter

Current filters:

LucentisPharmaceutical

1 to 9 of 69 results

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

16-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has compared trial data on German…

BayerEyleaGermanyLucentisNovartisOphthalmicsPharmaceuticalPricingRegulationRoche

Age-related macular degeneration treatment market to reach $10 billion by 2023

Age-related macular degeneration treatment market to reach $10 billion by 2023

04-12-2014

The market for treatments of age-related macular degeneration across seven major countries will almost…

AvastinEuropeEyleaFovistaLucentisMarkets & MarketingOphthalmicsPharmaceuticalUSA

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

12-11-2014

The Health & Social Care Information Centre has published its report on the prescribing habits of the…

HumiraLucentisMarkets & MarketingNational Health ServicePharmaceuticalResearchUKUnited Kingdom

Report shows Eylea and Lucentis are equally likely to be covered by payers

Report shows Eylea and Lucentis are equally likely to be covered by payers

19-09-2014

Recently launched anti-vascular endothelial growth factor (VEGF) agent Eylea (aflibercept), from USA-based…

EyleaFinancialGenentechLucentisOphthalmicsPharmaceuticalRegeneron PharmaceuticalsUSA

Novartis shows leadership in ophthalmology at EURETINA

Novartis shows leadership in ophthalmology at EURETINA

14-09-2014

New data on Swiss pharma major Novartis’ ophthalmic drugs Lucentis (ranibizumab) and Jetrea (ocriplasmin)…

JetreaLucentisNovartisOphthalmicsPharmaceuticalResearch

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

Drug policy expert calls for “nip in the bud” for AMD therapy drug substitute

16-06-2014

Steven Bradshaw, a UK-based drug policy expert and former ophthalmologist, is disappointed at the news…

AvastinEuropeItalyLucentisOphthalmicsPharmaceuticalRegulationRoche

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

Novartis presents real world data for Lucentis

Novartis presents real world data for Lucentis

09-05-2014

Swiss drug major Novartis has reported data on the eye drug Lucentis (ranibizumab) at the 2014 Association…

AMDEuropeHealthLucentisMajorMedicineNovartisOphthalmicsOphthalmologyPharmaceuticalResearch

1 to 9 of 69 results

COMPANY SPOTLIGHT

Menarini

Back to top